COMPASS Pathways (CMPS)
(Delayed Data from NSDQ)
$4.34 USD
-0.01 (-0.23%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.38 +0.04 (0.92%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMPS 4.34 -0.01(-0.23%)
Will CMPS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPS
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
CMPS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CMPS
Compass Pathways: Overly Confident Management Or Overly Skeptical Market
Compass Pathways (CMPS) Rating Maintained at Buy by Canaccord Genuity | CMPS Stock News
Compass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ...
Q2 2025 Compass Pathways PLC Earnings Call Transcript
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks